TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02445794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cohort
Description: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cohort
Description: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose cohort
Description: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose cohort
Description: RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.
Study: NCT01146587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GangTrainer GT1
Description: 30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: 30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: 60 minutes of Conventional Physiotherapy every workday for 8 weeks
Study: NCT02975557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 0.15%
Description: Brimonidine 0.15% eye drops 2 times a day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 0.075%
Description: Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
Study: NCT01895478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACCI-ED use
Description: Attending physicians were allowed to view the patient's PACCI-ED prior to completing the assessment form. Attendings were told at the time of the child's ED visit that the PACCI-ED is used to assess a child's asthma control and medication adherence, and that they could use it to complete the outcomes assessment form.
Study: NCT02724397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCI/BLI then white endoscopy
Description: First use of Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy to detect colonic adenomas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: White endoscopy and then LCI/BLI
Description: First use of White Light Endoscopy and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) to detect colonic adenomas.
Study: NCT02037555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AT-III (Human)
Description: AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride for Injection, United States Pharmacopeia
Study: NCT00600977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicine
Description: 9mg/m² J1 J4 2 COURSES

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicine pegylated
Description: 40 MG/M² J1 2 courses
Study: NCT03050229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin 10mg/day once daily before or after breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily before or after breakfast
Study: NCT02237222

Intervention type: OTHER
Intervention: Gait rehabilitation
Study: NCT00612807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly marital therapy
Description: Weekly marital therapy for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
Description: Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
Description: Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)
Study: NCT00849095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol combination (PRN)
Description: budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide/formoterol combination
Description: budesonide/formoterol 160/4.5 mcg 1 inhalation bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: bid inhaled placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terbutaline
Description: as needed terbutaline 500 mcg for a period of 52 weeks
Study: NCT00800254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: NMES 20 minutes twice a day for 6 weeks plus standard physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation Protocol
Description: Standard physical therapy for 8 weeks after surgery
Study: NCT02172417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cimetidine + Tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine + Tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Study: NCT01771341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAQUET SERVOi ventilator with Edi Catheter
Description: NAVA respiratory modality

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MAQUET SERVOi ventilator
Description: Pressure Support
Study: NCT02408159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varicella Zoster Vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03790033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ucha-Shinki-Hwan
Description: Product name : Bosinji Granule Manufacturer : Tsumura \& Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo granule
Study: NCT04586842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based Occupational Therapy
Description: Domiciliary and Community-based Occupational Therapy on mental health and ABI intervention, developed on the basis of the Model Of Human Occupation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard community-based intervention
Description: Interventions received at the community, public or private level (e.g. community nursing, social education and/or psychology).
Study: NCT01454817

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life
Description: Improving Quality of Life

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of life
Description: Improving Quality of Life
Study: NCT01836978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
Study: NCT02427464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engensis (VM202)
Description: gene therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04476004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scapular-focused exercise
Description: scapular-focused exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular-focused exercise
Description: scapular-focused exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual feedback
Description: EMG visual feedback
Study: NCT02106819

Intervention type: BEHAVIORAL
Intervention: Testing of emotional communication ability
Description: Assessment of comprehension and expression of emotional facial and prosodic expressions and assessment of emotional reactivity via ratings of emotionally evocative pictures and words.

Intervention type: BEHAVIORAL
Intervention: Testing of emotional communication ability
Description: Assessment of comprehension and expression of emotional facial and prosodic expressions and assessment of emotional reactivity via ratings of emotionally evocative pictures and words.

Intervention type: PROCEDURE
Intervention: magnetic resonance imaging (MRI) of the brain
Description: Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.

Intervention type: PROCEDURE
Intervention: magnetic resonance imaging (MRI) of the brain
Description: Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.
Study: NCT01548833

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delefilcon A contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delefilcon A contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narafilcon A contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filcon II 3 contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filcon II 3 contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filcon II 3 contact lens
Description: Silicone hydrogel contact lens for single use, daily disposable wear
Study: NCT03288142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertension Coaching Application and Home Monitor
Description: The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Tracking Application and Home Monitor
Description: Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
Study: NCT03170180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: sunitinib 37.5mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Imatinib 400mg daily
Study: NCT02046759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist- Intervention
Description: Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.
Study: NCT03903315

Intervention type: OTHER
Intervention: Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment
Description: Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment with reference to mortality and complications.

Intervention type: OTHER
Intervention: Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment
Description: Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment with reference to mortality and complications.
Study: NCT01859520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: swim-up, density gradient sperm preparation techniques
Description: Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
Study: NCT02879006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chinese Herbal Medication
Description: Capsules, 26 month course, starting 2 months pre-OIT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: 4 months course, starting 2 months pre-OIT through the 2 month build-up phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab
Description: 4 months course, starting 2 months pre-OIT through the 2 month build-up phase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi OIT
Description: 24 months of multi OIT (maintenance dose of 1gm each food allergen)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multi OIT
Description: 24 months of multi OIT (maintenance dose of 1gm each food allergen)
Study: NCT00715910

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nimenrix
Description: One dose, as intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nimenrix
Description: One dose, as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: One dose, as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: One dose, as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: One dose, as intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: One dose, as intramuscular injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
Study: NCT01700387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: onabotulinumtoxinA
Description: All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period.
Study: NCT02974699

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potato Starch (Bob's Red Mill)
Description: Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pregelatinized Starch (Resource ThickenUp)
Description: Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.
Study: NCT04052256

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary computed tomography angiography
Description: Computational fluid dynamic model information derived from CT
Study: NCT02481453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator: placebo
Study: NCT04424953

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath videolaryngoscope
Description: A brand of a commonly-used videolaryngoscope which has a camera at the end of the laryngoscope to visualize the vocal cords

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope
Description: Classic direct laryngoscope that depends on visualization of the vocal cords by the operator
Study: NCT04052178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS active and sham
Description: Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PES active and sham
Description: Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin active and placebo
Description: Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.